GSK’s ViiV Sues Hetero to Block Copies of Tivicay HIV Drug

GlaxoSmithKline Plc’s ViiV Healthcare Co. alleges in a federal lawsuit that Hetero Labs Ltd.’s proposed copy of the blockbuster Tivicay infringes a patent for the HIV treatment that doesn’t expire for another six years.

ViiV and Shionogi & Co. allege that Hetero’s generic version infringes US Patent No. 9,242,986, which Shionogi licenses exclusively to co-plaintiff ViiV Healthcare UK (No. 3) Ltd., according to a complaint filed Friday in the US District Court for the District of Delaware.

• The patent expires in June 2030, according to the US Food and Drug Administration’s registry of approved drugs, the Orange Book. The ...